Hot Topics at ASCO-GI 2022

Milind M. Javle, MD

Hot Topics at ASCO-GI 2022

ASCO GI Highlights

Videos — January 28, 2022

Featuring:

Milind M. Javle, MD

Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair
NCI Task Force: Hepatobiliary Cancers

Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.

By Milind M. Javle, MD

Letter from the Editor-in-Chief

September 2023, Vol 4, No 3

As we approach the fall season, it is wonderful to reflect on some of the amazing research presented this year, most recently at the ASCO 2023 annual meeting. One of the major highlights of ASCO this year included the results of HER2/neu-directed novel therapies in biliary cancer. Shubham Pant, MD, MBBS, from MD Anderson Cancer Center, presented the results of the HERIZON-1 clinical trial of the bispecific antibody zanidatamab in HER2/neu-expressing biliary cancers.

Annual CCF Conference Brings Together All Stakeholders

By Milind M. Javle, MD

Letter from the Editor-in-Chief

June 2023, Vol 4, No 2

This issue of CCA News highlights the Cholangiocarcinoma Foundation (CCF) 10th Annual Conference held in April. This meeting was chaired by Dr Chiara Branconi, a Lord Kelvin Adam Smith Reader at the University of Glasgow and a medical oncologist with Beatson Cancer Centre; and Dr Laura Goff, medical director of the Vanderbilt-Ingram Cancer Center’s Hematology and Oncology Division.

Characterization of Long-Term Survivors in TOPAZ-1

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1

Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.

MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1

The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.

Exciting New Abstracts from the ASCO GI Cancers Symposium

By Milind M. Javle, MD

Letter from the Editor-in-Chief

March 2023, Vol 4, No 1

Dr Javle provides his perspective on important abstracts presented at the ASCO Gastrointestinal Cancers Symposium, held January 19-21, 2023, in San Francisco, CA.

Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1

Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.

Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1

CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.

Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1

Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.

Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC

Chemotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1

The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.

JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection

Chemotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1

A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.

Hot Topics at ASCO-GI 2022

Featuring:

Subscribe Today!

I'd like to receive:

Stay In The Know

Hot Topics at ASCO-GI 2022

Featuring:

Related Items

Subscribe Today!

I'd like to receive:

Stay In The Know